| 1.52 0.07 (4.83%) | 12-01 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.95 | 1-year : | 2.25 |
| Resists | First : | 1.67 | Second : | 1.92 |
| Pivot price | 1.54 |
|||
| Supports | First : | 1.25 | Second : | 1.03 |
| MAs | MA(5) : | 1.45 |
MA(20) : | 1.53  |
| MA(100) : | 1.6 |
MA(250) : | 1.24 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 17 |
D(3) : | 13.7 |
| RSI | RSI(14): 48.9 |
|||
| 52-week | High : | 2.52 | Low : | 0.55 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BLRX ] has closed above bottom band by 43.4%. Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.48 - 1.49 | 1.49 - 1.5 |
| Low: | 1.35 - 1.36 | 1.36 - 1.37 |
| Close: | 1.44 - 1.45 | 1.45 - 1.46 |
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Mon, 20 Nov 2023
BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire
Mon, 13 Nov 2023
BioLineRx to Report Third Quarter 2023 Results on November 20 ... - Yahoo Finance
Tue, 07 Nov 2023
Biolinerx shares climb after $270M+ motixafortide deal in Asia with ... - BioWorld Online
Thu, 12 Oct 2023
BioLineRx Announces Closing of Exclusive License Agreement to ... - PR Newswire
Thu, 28 Sep 2023
BioLineRx Announces Encouraging Data from Pilot Phase of Phase ... - PR Newswire
Mon, 18 Sep 2023
Assessing BioLineRx As A Buy After Drug Approval (NASDAQ:BLRX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 874 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 5.2 (%) |
| Shares Short | 491 (K) |
| Shares Short P.Month | 2,560 (K) |
| EPS | -0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.8 % |
| Return on Equity (ttm) | -152.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -2.02 |
| PEG Ratio | 0 |
| Price to Book value | 151 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|